The main aim of this study is The IDEA coordinated effort showed that the kind and term of adjuvant chemotherapy in stage III colon cancer (CC) could be changed by the timetable of chemotherapy and the degree of danger. We pointed toward assessing the execution of IDEA’s outcomes, in actuality, practice for stage III CC. All clinicians enrolled in the French oncology agreeable gatherings GERCOR, FFCD, and UNICANCER GI mailing records were welcome to partake to an online anonymized cross country overview from January 30, 2019 to March 31, 2019. Extents were analyzed utilizing the χ 2 test. A sum of 213 doctors addressed the study. Of these, 173 (81%) thought about that 3 months of adjuvant chemotherapy was the new norm of care for generally safe (pT1-3/N1) stage III CC, and 99% thought about that a half year stayed the norm of care for high-hazard (pT4 or potentially pN2) stage III CC. In patients under 70 years, capecitabine and oxaliplatin (CAPOX) for a very long time was endorsed by 74% of the members in okay CC, while a half year of 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) was liked for high-hazard CC in 94% of cases.
Reference link- https://www.clinical-colorectal-cancer.com/article/S1533-0028(20)30158-4/fulltext